TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy
TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Since the first lysine-specific demethylase (KDM), lysine-specific demethylase 1 (LSD1), was characterized in 2004, several families of KDMs have been identified. LSD1 can specifically demethylate H3K4me1/2, H3K9me1/2 as well as some nonhistone substrates. It has been demonstrated to be an oncogene as well as a drug target. Hence, tens of small-mol...
Alternative Titles
Full title
TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1789760974
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1789760974
Other Identifiers
ISSN
1750-1911
E-ISSN
1750-192X
DOI
10.2217/epi-2015-0002
